{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:54:55Z","timestamp":1794952495453,"version":"4.9.1"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,1,18]],"date-time":"2005-01-18T00:00:00Z","timestamp":1106006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002It is uncertain whether ursodeoxycholic acid therapy slows down the progression of primary biliary cirrhosis, according to two meta\u2010analyses. However, the randomized trials evaluated had only a median of 24\u2003months of follow\u2010up.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To evaluate long\u2010term ursodeoxycholic acid therapy in primary biliary cirrhosis.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002We evaluated 209 consecutive primary biliary cirrhosis patients, 69 compliant with ursodeoxycholic acid and 140 untreated [mean follow\u2010up 5.79 (s.d.\u2003= 4.73) and 4.87 (s.d.\u2003=\u20035.21) years, respectively] with onset of all complications documented. Comparison was made following adjustment for baseline differences according to Cox modelling, Mayo and Royal Free prognostic models.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002Bilirubin and alkaline phosphatase concentrations improved with ursodeoxycholic acid (at 36\u2003months, <jats:italic>P<\/jats:italic>\u2003=\u20030.007 and 0.018, respectively). Unadjusted Kaplan\u2013Meier analysis showed benefit (<jats:italic>P<\/jats:italic>\u2003= 0.028), as 44 (31%) untreated and 15 (22%) ursodeoxycholic acid patients died or had liver transplantation. However, there was no difference when adjusted by Cox modelling (<jats:italic>P<\/jats:italic>\u2003=\u20030.267), Mayo (<jats:italic>P<\/jats:italic>\u2003=\u20030.698) and Royal Free models (<jats:italic>P<\/jats:italic>\u2003=\u20030.559). New pruritus or fatigue or other complications were not different, either before or after adjustment for baseline characteristics.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002Long\u2010term ursodeoxycholic acid therapy did not alter disease progression in primary biliary cirrhosis patients despite a significant improvement in serum bilirubin and alkaline phosphatase consistent with, and similar to, those seen in ursodeoxycholic acid cohorts in randomized trials.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02318.x","type":"journal-article","created":{"date-parts":[[2005,2,4]],"date-time":"2005-02-04T09:27:25Z","timestamp":1107509245000},"page":"217-226","source":"Crossref","is-referenced-by-count":30,"title":["Long\u2010term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow\u2010up to 12\u2003years"],"prefix":"10.1111","volume":"21","author":[{"given":"C. W.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gunsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Feudjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rigamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vlachogiannakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. K.","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,18]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199611213352107"},{"key":"e_1_2_11_3_2","first-page":"CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"1","author":"Gluud C","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11293-X"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)72401-6"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04047.x"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.5984"},{"key":"e_1_2_11_8_2","first-page":"392","article-title":"Ursodeoxycholic therapy in chronic liver disease: a meta\u2010analysis in primary biliary cirrhosis and in chronic hepatitis","volume":"89","author":"Simko V","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100102"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780111307"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840190512"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1994.tb01237.x"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05923.x"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.20894"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90771-P"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220311"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.4065\/72.12.1137"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80214-4"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709000190"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(89)91698-3"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80216-0"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90696-7"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105303242204"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.2.133"},{"key":"e_1_2_11_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(89)90045-7"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0950-3528(89)90052-3"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31880"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.31607"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02318.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02318.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:49:36Z","timestamp":1697230176000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02318.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,18]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02318.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02318.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,18]]}}}